DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 4 Morgan Stanley - 3 Eli Lilly's Mounjaro - 2 Sanjay Gupta ” - 1 Goldman Sachs - 1 Meg Tirrell John Nowak “ - 1 Meg Tirrell - 1 Sanjay Gupta - 1
Top related locs:
GLP U.S Seattle , Washington , U.S Xinhua Provo , Utah New York City Manhattan Brooklyn
Top related orgs:
Trilliant Health - 4 Novo Nordisk - 4 Nordisk - 2 PepsiCo - 2 Walmart - 2 Bank of America - 2 Health - 2 CNN - 1

Search resuls for: "Trilliant Health"


10 mentions found


☆ How to access the new weight loss drugs
  + stars: | 2024-02-15 | by ( Andrea Kane | ) edition.cnn.com   time to read: +7 min
(CNN) — By now, it is pretty clear that the new weight loss and diabetes medications have achieved blockbuster status. Unlike previous weight loss medications, they are pretty effective at helping people lose weight and keep it off — between around 15% to 20% of body weight — with relatively few side effects (although some people can’t tolerate them, and a fraction of patients experience more severe side effects). Zepbound, the newly approved weight loss drug from Eli Lilly, may be easier to find. “Otherwise, some physicians are prescribing older, generic weight loss medications that can be helpful for some patients.”These drugs are not right for everyoneFor many people, the cultural pressure to look a certain way is high. And join us next week on the Chasing Life podcast when we talk to WeightWatchers CEO Sima Sistani about whether these new weight loss drugs really signal the end of diet culture.
Persons: Sanjay Gupta ”, Eli Lilly, Goldman Sachs, Meg Tirrell John Nowak “, Meg Tirrell, Sanjay Gupta, ” Tirrell, “, ” Eli Lilly, Tirrell, ”, Sima Sistani Organizations: CNN, —, Trilliant Health, Novo Nordisk, US Food and Drug Administration, “, Nordisk, ”
☆ How Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
  + stars: | 2023-10-10 | by ( Natalie Rice | ) www.cnbc.com   time to read: +2 min
Danish drugmaker Novo Nordisk has entered a new chapter in its 100-year history — thanks to its newfound success with two products: Ozempic and Wegovy. Their skyrocketing popularity has boosted Novo Nordisk to new heights. Novo Nordisk's share price has more than quadrupled in the past five years, making it Europe's most valuable company by market cap. "It's clear that nobody had expected that it would be taking off this quickly," said Novo Nordisk CEO Lars Fruergaard Jørgensen in August. In 2018, the first full year with Ozempic on the market, Novo Nordisk's net sales were 111.8 billion Danish krone, or $17.7 billion, using an average exchange rate at the time.
Persons: Lars Fruergaard Jørgensen, Ozempic, Jared Holz, Semaglutide, Eli Lilly, Mounjaro Organizations: Nordisk, Novo Nordisk, Nordisk's, Novo Nordisk's, Trilliant Health, Mizuho, Pfizer, Food and Drug Administration
☆ Food retailers and producers are getting slammed as GLP-1 drugs like Ozempic raise growing alarms about demand
  + stars: | 2023-10-06 | by ( Matthew Fox | ) www.businessinsider.com   time to read: +3 min
The rise of GLP-1 drugs is driving consumer-staple stocks lower as patients eat less food. Walmart's US CEO said he'd already seen patients using GLP-1 drugs buy less food at the retailer. AdvertisementAdvertisementConsumer-staple stocks have been slammed this week as investors try to size up the negative impact GLP-1 drugs such as Ozempic, Wegovy, and Mounjaro could have on food companies. And through its pharmacy unit, the company can use anonymized data to analyze the spending habits of its customers that are taking GLP-1 drugs. AdvertisementAdvertisementIn a Friday note, Bank of America estimated that GLP-1 drugs could quell addictive behaviors among consumers, which could lead to an overall decline in consumption of snacks and beverages.
Persons: he'd, —, McDonald's, John Furner, Jeff Johnson, Baird, Morgan Stanley Organizations: PepsiCo, Coca, Cola, Walmart, Costco, Service, Bloomberg, Bank of America Locations: GLP
☆ Big Food vs. Big Pharma: Companies bet on snacking just as weight loss drugs boom
  + stars: | 2023-10-01 | by ( Amelia Lucas | ) www.cnbc.com   time to read: +3 min
But food companies' major bets on snacking come as investors fear the looming danger of Big Pharma's blockbuster obesity and diabetes drugs Wegovy and Ozempic. Younger generations snack more often than older consumers, said Kelsey Olsen, food and drink analyst for market research firm Mintel. Millennials and Gen-Z consumers tend to eat smaller meals that are closer together, creating more occasions to grab a snack. At the same time, Novo Nordisk's Ozempic and Wegovy have taken off, fueled by prescriptions to help patients lose weight. Some patients even report developing aversions to foods with higher sugar and fat content — a category that includes many big snack brands.
Persons: Smucker, Big, Wegovy, snacking, Kelsey Olsen, Millennials, Morgan Stanley, Morgan Stanley's, General Mills Organizations: Hostess Brands, HSBC, Accenture, Novo Nordisk's Ozempic, Hershey, Mondelez, PepsiCo, General Locations: Seattle , Washington , U.S, U.S
☆ Insurers and drug-industry middlemen are cashing in on the weight-loss drug frenzy
  + stars: | 2023-09-28 | by ( ) www.businessinsider.com   time to read: +5 min
Insurers and the drug-industry middlemen they own stand to earn more as healthcare spending increases. AdvertisementAdvertisementFor US health insurers, explosive demand for new weight-loss drugs likely means bigger profits. Insurers and the drug-industry middlemen they own stand to earn more as weight-loss drugs drive up healthcare spending, BofA analysts wrote. Meanwhile, if the drugs help people live longer, insurers could earn more from higher enrollment in their health plans. As weight-loss drugs drive up healthcare spending, insurers will make more moneyWeight-loss drugs, which can cost around $1,000 a month, are driving up healthcare spending.
Persons: Li Ran, Brian Evanko, Evernorth Organizations: Trilliant Health, Bank of America Global Research, Getty, Cigna, CVS Health, UnitedHealth Group, CVS, Kaiser Family Foundation Locations: Xinhua, GLP
☆ Will weight loss drugs lead to less food consumption? Here's what Walmart is saying
  + stars: | 2023-09-27 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +5 min
While there has been a huge gain, it is barely scratching the surface of the potential market. Some potential patients don't have coverage of the pricey medicines through their health insurance plans yet. (For example, those seeking to use GLP-1 drugs for obesity can't receive coverage if they are insured by Medicare as the federal health plan is not allowed to cover weight loss drugs.) Walmart told Bank of America that fiscal second-quarter sales benefited roughly 1% from GLP-1 drug sales volumes. Its stock has fallen 45% year to date on fears that these drugs will shrink the company's market potential.
Persons: John Rainey, Eli Lilly's Mounjaro, Eli Lilly, Morgan Stanley, Wells, Larry Biegelsen, Biegelsen, Daniel Lyons, Janus Henderson, Lyons, — CNBC's Michael Bloom Organizations: Wall Street, Nordisk's Wegovy, Bank of, Walmart, Health, Novo Nordisk, Medicare, Drug, Bank of America, Janus, Janus Henderson Investors, CNBC Locations: U.S, GLP
☆ Ozempic, Wegovy drug prescriptions hit 9 million, surge 300% in under three years
  + stars: | 2023-09-27 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
U.S. health care providers wrote more than nine million prescriptions for Ozempic, Wegovy and similar diabetes and obesity drugs during the last three months of 2022, according to a new analysis released Wednesday. Among the other drugs prescribed are Eli Lilly's diabetes drug Mounjaro and an older GLP-1 drug from Novo Nordisk called Saxenda, which isn't as effective for weight loss as Ozempic and Wegovy. Ozempic's list price tops $935 per monthly package, and its weight loss counterpart Wegovy is about $1,300. Other drugmakers are jockeying to capitalize on the budding weight loss industry. And analysts say Eli Lilly's Mounjaro has the potential to overtake drugs from Novo Nordisk after its approved in the U.S. for weight loss.
Persons: Eli Lilly, Eli, Elon Musk, Eli Lilly's Mounjaro Organizations: Novo Nordisk, Pharmacy, Health, National Institutes of Health Locations: Provo , Utah, U.S
☆ The N.Y.C. Neighborhood That’s Getting Even Thinner on Ozempic
  + stars: | 2023-08-26 | by ( Joseph Goldstein | More About Joseph Goldstein | ) www.nytimes.com   time to read: +1 min
The Upper East Side is one of the city’s wealthiest and healthiest neighborhoods. It has one of the highest life expectancies, and among the lowest rates of diabetes and obesity in New York City. Now the neighborhood’s residents are getting even thinner. That was the highest rate in New York City. “The running game show of the 10021 ZIP code is guessing who is on Vitamin O” — that is, Ozempic, said the writer, actress and Upper East Side native, Jill Kargman, referring to what has long been the city’s toniest ZIP code, covering much of the East 70s.
Persons: Jill Kargman Organizations: Gramercy, Trilliant Health Locations: New York City, Manhattan, Brooklyn
☆ Adderall users struggle amid ongoing medication shortage
  + stars: | 2022-11-17 | by ( Raenu Charles | ) edition.cnn.com   time to read: +7 min
A report from data analytics firm Trilliant Health found that nationally, prescriptions for Adderall among people ages 22 to 44 increased 15% between 2020 and 2021. “I’ve had patients call 10,15, 20 pharmacies in order to get their medication,” Goodman said. Clara is headed to her doctor to seek an alternative medication until Adderall is back in stock. It took five days for his pharmacy to fill his prescription in late October, and those days took a toll. Goodman strongly warns against this, offering a reminder that not only is selling your own prescription medication a felony, so is sharing it with others.
☆ Cancer diagnoses lag after screenings fall during pandemic, U.S. study finds
  + stars: | 2022-11-17 | by ( Shawana Alleyne-Morris | ) www.reuters.com   time to read: +2 min
The decrease in diagnoses "does not mean these cancers are suddenly less common," said study leader Allison Oakes of data analytics company Trilliant Health in Brentwood, Tennessee. By the end of 2021, screening rates had rebounded but were still below pre-pandemic levels, researchers reported in JAMA Oncology. Ongoing analysis of 2022 data suggests screening rates in 2022 are unlikely to have improved dramatically, Oakes said. The issue appears to go beyond cancer testing, the study found. "Not only are people missing their annual cancer screenings, but they are using less primary care," Oakes said.
0 next >>
Total: 10